Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hereditary factors and exposures in childhood associated with adult chronic rhinosinusitis-the RHINE study.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2026
Same author

Uncommon finding in a pulmonary graft versus host disease: A first report of Tsukamurella pneumonia in a pulmonary graft-versus-host disease.

IDCases·2024
Same author

Adjuvant surgical treatment of non-tuberculous mycobacterial lung disease in chronic thromboembolic pulmonary hypertension: A first case report.

Journal of clinical tuberculosis and other mycobacterial diseases·2024
Same author

An observational analysis on the influence of parental allergic rhinitis, asthma and smoking on exhaled nitric oxide in offspring.

Nitric oxide : biology and chemistry·2024
Same author

Alpha-1 deficiency in severe asthma patients.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same author

Association between lung function and dyspnoea and its variation in the multinational Burden of Obstructive Lung Disease (BOLD) study.

Pulmonology·2024
Same journal

Beyond the 5th percentile: rethinking diagnostic thresholds in pulmonary function testing.

The European respiratory journal·2026
Same journal

A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction.

The European respiratory journal·2026
Same journal

Risk of cancer and mortality in patients with interstitial lung diseases: Danish cohort study.

The European respiratory journal·2026
Same journal

Proposing a minimal important difference in NTproBNP in pulmonary arterial hypertension.

The European respiratory journal·2026
Same journal

Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis.

The European respiratory journal·2026
Same journal

Decoding the Lymphangioleiomyomatosis (LAM) Niche Microenvironment <i>via</i> Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics.

The European respiratory journal·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

ADRB2 Gly16Arg polymorphism, asthma control and lung function decline.

C Rebordosa1, M Kogevinas, S Guerra

  • 1Centre for Research in Environmental Epidemiology, Hospital del Mar Research Institute (IMIM), Barcelona, Spain. crebordo@email.arizona.edu

The European Respiratory Journal
|March 26, 2011
PubMed
Summary
This summary is machine-generated.

The Gly16Arg polymorphism in the β₂-adrenoreceptor gene (ADRB2) is linked to poorer asthma control and faster lung function decline. However, inhaled corticosteroid (ICS) or long-acting β₂-agonist (LABA) use may mitigate these effects.

Related Experiment Videos

Last Updated: Jun 3, 2026

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

Area of Science:

  • Pharmacogenetics
  • Respiratory Medicine
  • Genetics

Background:

  • The Gly16Arg polymorphism in the β₂-adrenoreceptor gene (ADRB2) influences receptor function.
  • Arg/Arg homozygotes show reduced response to short-acting β₂-agonists.
  • The impact of this polymorphism on asthma control and lung function with different medication use is not fully understood.

Purpose of the Study:

  • To investigate the association between the Gly16Arg polymorphism and asthma control.
  • To determine if this polymorphism affects lung function decline.
  • To examine if the use of long-acting β₂-agonists (LABAs) or inhaled corticosteroids (ICS) modifies these associations.

Main Methods:

  • 604 asthma patients from the European Community Respiratory Health Study were analyzed.
  • Asthma control, lung function decline (FEV₁), and bronchial hyperresponsiveness (BHR) were assessed.
  • Genotyping for the Gly16Arg polymorphism in the ADRB2 gene was performed.

Main Results:

  • Each Arg allele increased the risk of noncontrolled asthma (OR 1.33).
  • Among non-ICS users, Arg/Arg homozygotes had a significantly higher risk of noncontrolled asthma (OR 2.73).
  • A faster annual decline in FEV₁ (7.7 mL·yr⁻¹) was associated with each Arg allele, independent of ICS/LABA use.
  • Arg/Arg homozygotes without ICS use showed increased BHR (OR 2.51).

Conclusions:

  • The Arg allele of the Gly16Arg polymorphism is associated with poorer asthma control, accelerated lung function decline, and increased bronchial hyperresponsiveness.
  • ICS and/or LABA use may counteract the negative effects of the Arg allele on asthma control.
  • The absence of genotypic effects on asthma control in ICS users might be due to reversed β₂-adrenoreceptor desensitization.